Tools

LEADER 02409nam 2200469 i 4500

001 ssj0001709492;

003 WaSeSS;

005 20251212090320.0;

006 m d ;

007 cr n ;

008 151106s2019 flua sb 001 0 eng d;

010 a| 2015043743;

020 a| 9781498750394 (hardcover : acid-free paper);

035 a| (WaSeSS)ssj0001709492;

040 a| DNLM/DLCc| DLCd| DLCd| WaSeSS;

042 a| pcc;

049 a| EREEa| NEHH;

050 00 a| RS67.U6b| N53 2019;

060 10 a| QV 241;

082 00 a| 615.109732| 23;

100 1 a| Niazi, Sarfaraz,d| 1949-?| UNAUTHORIZED;

245 10 a| Biosimilarityh| [electronic resource] :b| the FDA perspective /c| Sarfaraz K. Niazi, PhD, SI, FRSB, FPAMS, FACB, Adjunct Professor, Biopharmaceutical Sciences, University of Illinois (U.S.), University of Houston (U.S.), HEJ Research Institute (PK), and National University of Science and Technology (PK), Founder, Karyo Biologics, LLC (U.S.), Adello Biologics (U.S.), and Pharmaceutical Scientist, INC (U.S.).;

260 a| Boca Raton :b| CRC Press, Taylor & Francis Group,c| [2019];

300 a| xxxvii, 397 pages :b| color illustrations ;c| 27 cm;

504 a| Includes bibliographical references and index.;

506 a| Available only to authorized users.;

538 a| Mode of access: World Wide Web;

610 12 a| United States.b| Food and Drug Administration.=| ^A1253;

650 12 a| Biosimilar Pharmaceuticalsz| United States.=| ^A1337705;

650 22 a| Drug Approvalz| United States.=| ^A928241;

650 22 a| Government Regulationz| United States.=| ^A938505;

650 22 a| United States Government Agenciesz| United States.=| ^A945536;

655 0 a| Electronic books.=| ^A491897;

856 40 z| Full text available from Taylor & Francis eBooksu| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fwww.taylorfrancis.com%2Fbooks%2F9781315368344;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 6658183;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6658183-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 12/18/2025x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6658183-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 12/18/2025x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6658183-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 12/18/2025x| EBOOKz| JERESOURCE;

Biosimilarity the FDA perspective / Sarfaraz K. Niazi, PhD, SI, FRSB, FPAMS, FACB, Adjunct Professor, Biopharmaceutical Sciences, University of Illinois (U.S.), University of Houston (U.S.), HEJ Research Institute (PK), and National University of Science and Technology (PK), Founder, Karyo Biologics, LLC (U.S.), Adello Biologics (U.S.), and Pharmaceutical Scientist, INC (U.S.).

Author/creator	Niazi, Sarfaraz, 1949-
Format	Electronic
Publication Info	Boca Raton : CRC Press, Taylor & Francis Group, [2019]
Description	xxxvii, 397 pages : color illustrations ; 27 cm
Supplemental Content	Full text available from Taylor & Francis eBooks
Subjects	United States. Food and Drug Administration. Biosimilar Pharmaceuticals--United States. Drug Approval--United States. Government Regulation--United States. United States Government Agencies--United States.

Bibliography note	Includes bibliographical references and index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
LCCN	2015043743
ISBN	9781498750394 (hardcover : acid-free paper)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Click here for more information about this title

Availability